Price$158.63+3.59 (+2.32%)
2026-07-162026-10-16
News · 26 weeks133-5%
2026-04-192026-10-11
Mix5690d
- Insider32(57%)
- Other14(25%)
- SEC Filings6(11%)
- Earnings2(4%)
- Analyst2(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Guardant Health Inc.4 - Guardant Health, Inc. (0001576280) (Issuer)
- PRTwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 PatentFollowing Federal Circuit remand, the PTAB again rules in favor of the University of Washington and TwinStrand on all 30 claims of the ’127 patent challenged by Guardant Health TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected Guardant Health, Inc.’s (NASDAQ:GH) challenge to a core patent underlying Duplex Sequencing. In an Oct. 14, 2026, Final Written Decision on remand from the U.S. Court of Appeals for the Federal Circuit, the PTAB ruled in favor of the University of Washington (UW), determining that Guardant Health failed to establish the
- PRGuardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based TestsModeling study provides strong data on real-world follow-up colonoscopy adherence and CRC deaths averted for blood-based testing vs stool-based testing New data demonstrates notable screening adherence rate of 99% in medically-underserved populations for Shield blood-based colorectal cancer (CRC) screening test Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening and follow-up colonoscopy adherence at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville, Ten
- SECSEC Form 144 filed by Guardant Health Inc.144 - Guardant Health, Inc. (0001576280) (Subject)
- INSIDERSEC Form 4 filed by Guardant Health Inc.4 - Guardant Health, Inc. (0001576280) (Issuer)
- PRGuardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast CancerGuardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographies This latest approval marks Guardant’s 31st CDx approval Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca’s next-generation oral selective estrogen receptor degrader (SERD) and complete ER antago
- PRGuardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012,
- PRGuardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in MelanomaFirst published prospective, multicenter study of Guardant Reveal in resected melanoma demonstrates 81% sensitivity for distant recurrence and 100% post-treatment specificity Molecular residual disease detection approximately four weeks after surgery was independently associated with an approximately 12-fold increased risk of recurrence and a greater than 30-fold increased risk of death Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicent
- INSIDERChief Legal Officer Saia John G. converted options into 7,063 shares and covered exercise/tax liability with 3,706 shares, increasing direct ownership by 9% to 42,348 units (SEC Form 4) (withholding obligation)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief People Officer Monroe Terilyn J. converted options into 4,019 shares and covered exercise/tax liability with 2,098 shares, increasing direct ownership by 8% to 24,900 units (SEC Form 4) (withholding obligation)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Information Officer Kalia Kumud converted options into 6,046 shares and covered exercise/tax liability with 3,067 shares, increasing direct ownership by 7% to 42,773 units (SEC Form 4) (withholding tax)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Commercial Officer Freeman Chris converted options into 7,416 shares and covered exercise/tax liability with 3,143 shares, increasing direct ownership by 7% to 69,647 units (SEC Form 4) (for tax liability)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Technology Officer Chudova Darya converted options into 8,033 shares and covered exercise/tax liability with 4,320 shares, increasing direct ownership by 5% to 74,348 units (SEC Form 4) (tax withholding)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Financial Officer Bell Michael Brian converted options into 7,280 shares and covered exercise/tax liability with 3,914 shares, increasing direct ownership by 6% to 55,182 units (SEC Form 4) to satisfy withholding tax4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERCo-Chief Executive Officer Talasaz Amirali covered exercise/tax liability with 18,515 shares and converted options into 36,530 shares (SEC Form 4) (tax withholding)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERCo-Chief Executive Officer Eltoukhy Helmy converted options into 36,530 shares and covered exercise/tax liability with 18,515 shares (SEC Form 4) (for tax liability)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Mignone Roberto converted options into 264 shares, increasing direct ownership by 3% to 10,274 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 5% to 5,020 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Technology Officer Chudova Darya sold $1,377,364 worth of shares (7,738 units at $178.00), decreasing direct ownership by 10% to 70,635 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Azar Alex M Ii sold $144,550 worth of shares (826 units at $175.00), decreasing direct ownership by 50% to 825 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Krognes Steve E. sold $1,172,886 worth of shares (6,674 units at $175.74), decreasing direct ownership by 46% to 7,906 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Tariq Musa converted options into 249 shares and sold $20,300 worth of shares (116 units at $175.00), increasing direct ownership by 1% to 11,449 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- SECSEC Form 144 filed by Guardant Health Inc.144 - Guardant Health, Inc. (0001576280) (Subject)
- INSIDERDirector Azar Alex M Ii converted options into 1,651 shares (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Information Officer Kalia Kumud sold $632,193 worth of shares (4,000 units at $158.05), decreasing direct ownership by 9% to 39,794 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
GH FAQ
7 questionsWhat does Guardant Health Inc. do?
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic...Where does GH stock trade?
Guardant Health Inc. (GH) is listed on NASDAQ.What sector and industry is GH in?
Guardant Health Inc. operates in the Health Care sector, Medical Specialities industry.When did Guardant Health Inc. go public?
Guardant Health Inc. (GH) completed its IPO in 2018.What are analysts saying about GH?
Guardant Health Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-09-09.What companies are similar to GH?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare GH side-by-side with any of them on Quantisnow.How can I track GH on Quantisnow?
Quantisnow aggregates Guardant Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GH to receive live email and push alerts on every new disclosure.